Showing results (171-180 of 194) with videos related to

Sort By:
Pageof 20
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
The Journal of Infectious Diseases|April 6, 2012
Clinical research and development of tuberculosis diagnostics: moving from silos to synergyPayam Nahid, Peter S Kim, Carlton A Evans, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The New England Journal of Medicine|March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related TuberculosisSusan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Plos One|March 17, 2023
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the householdSoyeon Kim, Anneke C Hesseling, Xingye Wu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2023
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant TuberculosisSonya Krishnan, Xingye Wu, Soyeon Kim, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2019
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional StudyNishi Suryavanshi, Matthew Murrill, Amita Gupta, et al.
Pageof 20